Access Bio/CareStart快速诊断试验检测葡萄糖-6-磷酸脱氢酶缺乏症的性能:系统综述与荟萃分析
该系统综述与个体患者荟萃分析评估CareStart筛查试验对比分光光度法诊断G6PD缺乏症的性能,纳入8项研究5777例数据,汇总敏感度0.96、特异度0.95,在30%阈值下表现良好,高阴性预测值适合指导伯氨喹治疗。
要点
- CareStart在30%酶活性阈值下汇总敏感度0.96、特异度0.95。
- G6PD缺乏症患病率5%–30%时,阴性预测值0.99,适合排除缺乏症。
- 男性检测性能显著优于女性(p=0.027),毛细血管与静脉血无显著差异。
核心结论
- CareStart在30%阈值下表现良好,高阴性预测值适合指导伯氨喹治疗,高阳性似然比和低阴性似然比适合确认和排除G6PD缺乏症。
研究设计与样本
- 系统综述与个体患者荟萃分析,检索PubMed 2011年1月1日至2019年9月27日发表文章,纳入8项研究共5777例个体数据(99.3%可分析),其中女性3095例(53.6%)。
主要发现
- 汇总敏感度0.96(95%CI 0.90-0.99),特异度0.95(95%CI 0.92-0.96)。
- 患病率5%至30%时,无条件阴性预测值0.99(95%CI 0.94-1.00),阳性似然比18.23(95%CI 13.04-25.48),阴性似然比0.05(95%CI 0.02-0.12)。
- 男性检测性能显著优于女性(p=0.027),毛细血管与静脉血样本间无显著差异(p=0.547)。
关键数值与推荐
- G6PD缺乏症定义为酶活性低于30%,调整男性中位数(AMM)定义为100% G6PD活性。
- 金标准为分光光度法(Trinity Biotech PLC试剂盒),CareStart为定性侧流试验。
临床怎么用
- 在伯氨喹根治间日疟前,可用CareStart筛查G6PD缺乏症以指导治疗决策。
- 高阴性预测值支持该试验用于排除G6PD缺乏症,高阳性似然比支持用于确认。
局限性
- 纳入数据缺乏广泛地理代表性,6项来自东南亚、1项非洲、1项美洲。
- CareStart结果在研究条件下生成,可能不反映常规环境中的性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994). METHODS AND FINDINGS: Articles published on PubMed between 1 January 2011 and 27 September 2019 were screened. Articles reporting performance of the standard CSG from venous or capillary blood samples collected prospectively and considering spectrophotometry as gold standard (using kits from Trinity Biotech PLC, Wicklow, Ireland) were included. Authors of articles fulfilling the inclusion criteria were contacted to contribute anonymized individual data. Minimal data requested were sex of the participant, CSG result, spectrophotometry result in U/gHb, and haemoglobin (Hb) reading. The adjusted male median (AMM) was calculated per site and defined as 100% G6PD activity. G6PDd was defined as an enzyme activity of less than 30%. Pooled estimates for sensitivity and specificity, unconditional negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) were calculated comparing CSG results to spectrophotometry using a random-effects bivariate model. Of 11 eligible published articles, individual data were available from 8 studies, 6 from Southeast Asia, 1 from Africa, and 1 from the Americas. A total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis, including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a specificity of 0.95 (95% CI 0.92-0.96). When the prevalence of G6PDd was varied from 5% to 30%, the unconditional NPV was 0.99 (95% CI 0.94-1.00), with an LR+ and an LR- of 18.23 (95% CI 13.04-25.48) and 0.05 (95% CI 0.02-0.12), respectively. Performance was significantly better in males compared to females (p = 0.027) but did not differ significantly between samples collected from capillary or venous blood (p = 0.547). Limitations of the study include the lack of wide geographical representation of the included data and that the CSG results were generated under research conditions, and therefore may not reflect performance in routine settings. CONCLUSIONS: The CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR- render the test suitable to confirm and exclude G6PDd. Further operational studies are needed to confirm the utility of the test in remote endemic settings.
引用
- Ley B, Winasti Satyagraha A, Rahmat H, et al. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis. PLoS Med. 2019. PMID: 31834890. doi:10.1371/journal.pmed.1002992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。